Clinical Trial Results: A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial in children aged 6 to 17 with heterozygous familial hypercholesterolemia evaluating once-daily bempedoic acid (CLEAR Path 1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Bempedoic Acid (bempedoic acid)

Snippet

Sponsor: Esperion Therapeutics, Inc. | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2026-07-17